Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment

NCT02099864 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT02099864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02099864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
February 5, 2014
Completion date
July 8, 2024
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic malignant neoplasm in the bone, metastatic malignant neoplasm in the soft tissues, metastatic prostate adenocarcinoma, recurrent prostate carcinoma, stage iii prostate adenocarcinoma ajcc v7, stage iv prostate adenocarcinoma ajcc v7